NCT05834595已完成1 期
An Open-label, Randomized, Fasted, Single-dose, 2-sequence, 4-period, Replicate Crossover Study to Compare the Pharmacokinetic and Safety Between Administration of CKD-828 20/2.5mg and Administration of D064, D701 in Healthy Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- AUCt of CKD-828
研究概览
简要总结
A clinical trial to compare the pharmacokinetic and safety of CKD-828
详细描述
An open-label, randomized, fasted, single-dose, 2-sequence, 4-period, replicate crossover study to compare the pharmacokinetic characteristics and safety between administration of CKD-828 20/2.5mg and administration of D064, D701 in healthy adults
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult aged ≥ 19 at screening
- •Body mass index (BMI) of 17.5 kg/m2 or more and less than 30.5kg/m2 and Body weight ≥ 55kg
- •Those who do not have congenital or chronic diseases and have no pathological symptoms or findings as a result of medical examination
- •A person who is deemed suitable as a subject as a result of screening such as clinical laboratory examination (hematology, blood chemistry, urinalysis, serological tests, etc.), vital signs, electrocardiogram examination, etc.
- •A person who has received a sufficient explanation of the purpose and contents of the clinical trial and has agreed in writing voluntarily to participate in the clinical trial
- •A person who has agreed to use appropriate contraception and not donate sperm or eggs until 14 days after the first administration of the drug and the last administration of the drug
- •Those who have the ability and willingness to participate during the entire study period
排除标准
- •A history of clinically significant blood, renal, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, psychiatric, neurological, or immune disease (except for simple dental history of calculus, impacted teeth, wisdom teeth, etc.) or evidence on who has
- •Those with a history of gastrointestinal diseases or surgery (expect simple appendicectomy, hernia surgery, and tooth extraction surgery) that may affect drug absorption ruler
- •A person who shows the following values as a result of conducting a clinical laboratory test
- •ALT or AST > 2 times the upper limit of the normal range
- •Smokers who smoked more than 20 cigarettes a day within 6 months of screening
- •Those who have taken other investigational product or bioequivalence investigational product within 6 months before the first administration of the investigational product
- •Those who meet the following as a result of measuring vital signs at screening
- •Those who have a systolic blood pressure of less than 90 mmHg or more than 140 mmHg or a diastolic blood pressure of less than 60 mmHg or more than 90 mmHg in the sitting position
- •Severe bradycardia (less than 50 beats/min)
- •Those with a history of regular alcohol intake within 1 month of screening
- •More than 14 drinks/week for women
- •More than 21 drinks/week for men
- •A person who has taken a drug known to significantly induce or inhibit drug metabolizing enzymes within 30 days before the first administration of investigational product
- •Those who have taken prescription or non-prescription drugs within 10 days prior to the first administration of investigational product
- •Those who have donated whole blood within 2 months before the first administration of the investigational product, donated component blood within 1 month, received blood transfusion within 1 month, or have plans for the trial during the clinical trial period
- •Those who are judged by the principal investigator (or the person in charge of the test who has been delegated) for reason other than the above selection/exclusion criteria and are judged unsuitable for participation in the study
研究组 & 干预措施
Sequence 1
Experimental
- Period 1: D064, D701 - A single oral dose of 2 tablets
- Period 2: CKD-828 - A single oral dose of 1 tablet
- Period 3: D064, D701 - A single oral dose of 2 tablets
- Period 4: CKD-828 - A single oral dose of 1 tablet
干预措施: CKD-828, D064, D701 (Drug)
Sequence 2
Experimental
- Period 1: CKD-828 - A single oral dose of 1 tablet
- Period 2: D064, D701 - A single oral dose of 2 tablets
- Period 3: CKD-828 - A single oral dose of 1 tablet
- Period 4: D064, D701 - A single oral dose of 2 tablets
干预措施: CKD-828, D064, D701 (Drug)
结局指标
主要结局
AUCt of CKD-828
时间窗: Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72 hours
Area under the concentration-time curve time zero to time
Cmax of CKD-828
时间窗: Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72 hours
Maximum plasma concentration of the drug
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy SubjectsHypertensionNCT05540912Chong Kun Dang Pharmaceutical30
已完成
1 期
A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mgHypertensionNCT05881707Chong Kun Dang Pharmaceutical44
已完成
1 期
CKD-828 (40/5mg) Pharmacokinetic StudyHypertensionNCT01340131Chong Kun Dang Pharmaceutical68
已完成
1 期
CKD-828(80/2.5mg) Pharmacokinetic Study_2ndHypertensionNCT01352689Chong Kun Dang Pharmaceutical67
已完成
1 期
CKD-828(80/2.5mg) Pharmacokinetic StudyHypertensionNCT01246193Chong Kun Dang Pharmaceutical65